Acumen Pharmaceuticals Inc (NASDAQ: ABOS)’s stock price has plunge by -0.97relation to previous closing price of 1.03. Nevertheless, the company has seen a -4.67% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-13 that Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Alex Braun – Head, Investor Relations Dan O’Connell – Chief Executive Officer Matt Zuga – Chief Financial Officer and CBO Dr. Jim Doherty – President and CDO Dr. Eric Siemers – Chief Medical Officer Conference Call Participants Sarah Medeiros – Cantor Fitzgerald Tom Shrader – BTIG Ting Liu – UBS Operator Good day and thank you for standing by. Welcome to the Acumen Pharmaceuticals Q1 2025 Conference Call and Webcast.
Is It Worth Investing in Acumen Pharmaceuticals Inc (NASDAQ: ABOS) Right Now?
Company’s 36-month beta value is 0.06.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ABOS is 44.28M, and currently, short sellers hold a 3.95% ratio of that floaft. The average trading volume of ABOS on May 25, 2025 was 218.72K shares.
ABOS’s Market Performance
ABOS stock saw a decrease of -4.67% in the past week, with a monthly decline of -7.27% and a quarterly a decrease of -26.62%. The volatility ratio for the week is 0.47%, and the volatility levels for the last 30 days are 3.89% for Acumen Pharmaceuticals Inc (ABOS). The simple moving average for the past 20 days is -1.72% for ABOS’s stock, with a -45.94% simple moving average for the past 200 days.
Analysts’ Opinion of ABOS
Many brokerage firms have already submitted their reports for ABOS stocks, with Citigroup repeating the rating for ABOS by listing it as a “Buy.” The predicted price for ABOS in the upcoming period, according to Citigroup is $7 based on the research report published on July 26, 2024 of the previous year 2024.
Deutsche Bank, on the other hand, stated in their research note that they expect to see ABOS reach a price target of $8. The rating they have provided for ABOS stocks is “Buy” according to the report published on December 12th, 2023.
BofA Securities gave a rating of “Buy” to ABOS, setting the target price at $14 in the report published on July 20th of the previous year.
ABOS Trading at -5.42% from the 50-Day Moving Average
After a stumble in the market that brought ABOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.75% of loss for the given period.
Volatility was left at 3.89%, however, over the last 30 days, the volatility rate increased by 0.47%, as shares sank -5.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.39% lower at present.
During the last 5 trading sessions, ABOS fell by -4.67%, which changed the moving average for the period of 200-days by -64.46% in comparison to the 20-day moving average, which settled at $1.0378. In addition, Acumen Pharmaceuticals Inc saw -40.70% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABOS starting from Zuga Matt, who sale 28,902 shares at the price of $1.72 back on Jan 23 ’25. After this action, Zuga Matt now owns 231,744 shares of Acumen Pharmaceuticals Inc, valued at $49,633 using the latest closing price.
Zuga Matt, the CFO & Chief Business Officer of Acumen Pharmaceuticals Inc, sale 4,364 shares at $1.60 during a trade that took place back on Jan 21 ’25, which means that Zuga Matt is holding 260,646 shares at $6,986 based on the most recent closing price.
Stock Fundamentals for ABOS
The total capital return value is set at -0.68. Equity return is now at value -55.68, with -46.00 for asset returns.
Based on Acumen Pharmaceuticals Inc (ABOS), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -3.53. The debt to equity ratio resting at 0.19. The interest coverage ratio of the stock is -30.95.
Currently, EBITDA for the company is -98.08 million with net debt to EBITDA at 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.02.
Conclusion
In a nutshell, Acumen Pharmaceuticals Inc (ABOS) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
